Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

(MedPage Today) — Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from the VALOR trial and its open…

Source link : https://www.medpagetoday.com/neurology/generalneurology/119165

Author :

Publish date : 2025-12-23 17:46:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

‘Armored’ CAR T Cells Show Early Promise in Relapsed B-Cell ALL

Six-Monthly HIV Prevention Injection Cleared by MHRA

Related Posts

Mortality After Menopausal Hormone Therapy: Study Weighs In

Exercise Cuts Cancer Mortality Risk in Less Common Types of Cancer, Too

Trump Team Taps New Acting CDC Director

Antibody-Oligonucleotide Conjugate Shows Promise in Myotonic Dystrophy Type 1

What Action Will RFK Jr. Take on Ultraprocessed Foods?

Q&A: ANA’s President on the Death of Nurse Alex Pretti and More

Mortality After Menopausal Hormone Therapy: Study Weighs In

Exercise Cuts Cancer Mortality Risk in Less Common Types of Cancer, Too

Trump Team Taps New Acting CDC Director

Antibody-Oligonucleotide Conjugate Shows Promise in Myotonic Dystrophy Type 1

What Action Will RFK Jr. Take on Ultraprocessed Foods?

Q&A: ANA’s President on the Death of Nurse Alex Pretti and More

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

Novel Rapid-Acting Drug Proves Effective in Severe PTSD

Categories

Archives